Je. Tisdale et al., DISPOSITION OF PROCAINAMIDE IN PATIENTS WITH CHRONIC CONGESTIVE-HEART-FAILURE RECEIVING MEDICAL THERAPY, Journal of clinical pharmacology, 36(1), 1996, pp. 35-41
Dosage reduction of procainamide has been recommended in patients with
congestive heart failure (CHF). However, these recommendations are ba
sed primarily on studies with unmatched control groups, suboptimal blo
od sampling, and in patients not receiving angiotensin-converting enzy
me (ACE) inhibitors. These agents increase renal blood flow, which the
oretically may offset alterations in drug disposition in patients with
CHF. The pharmacokinetics of procainamide in patients with chronic CH
F and in matched controls were compared, A single intravenous dose of
750 mg of procainamide was administered to 9 patients with chronic New
York Heart Association (NYHA) class II or III CHF (mean +/- SD left v
entricular ejection fraction 22 +/- 9%) receiving medical therapy and
7 control subjects matched for age and gender. Blood and urine samples
were collected at intervals over a period of 48 and 72 hours, respect
ively, Patients with CHF and control subjects were demographically sim
ilar, with the exception of concomitant medications, including ACE inh
ibitors (8/9 versus 1/7, respectively). There were no significant diff
erences between patients with CHF and control subjects in mean +/- SD
peak serum concentrations (C-max), area under the serum concentration-
time curve (AUC(0-infinity)), total clearance, renal clearance, half-l
ife (t(1/2)), or volume of distribution (Vd) of procainamide. Similarl
y, there were no significant differences between patients with CHF and
control subjects in the mean +/- SD C-max, AUC(0-infinity), renal cle
arance, or t(1/2) of N-acetylprocainamide (NAPA). Procainamide dosage
reduction may not be necessary in patients with chronic stable CHF who
are receiving medical therapy.